FDA Recommends Genetic Testing For Plavix Response, Opens Window For Effient
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA increased the level of its Plavix warning for slow metabolizers to a black box, recommending genetic testing and advising health care professionals to consider using other anti-platelet medications or alternative dosing strategies.
You may also be interested in...
Medco Buys DNA Direct To Bolster Its Personalized Medicine Business
DNA Direct adds genetic testing guidance and decision-support capacity to Medco's burgeoning personalized medicine portfolio.
Lilly Puts On A Happy Face, But Will Investors Buy In?
It was all about the pipeline during Eli Lilly's fourth quarter earnings call, as company execs strove to convince analysts they can compensate for revenue losses from big-ticket products about to lose patent protection
FDA Updates Plavix Label, Leaves Effient With Clear Advantage
FDA's latest revision of labeling for Bristol-Myers Squibb/Sanofi Aventis' Plavix gives Lilly/Daiichi Sankyo a clear-cut advantage to use for its competing antiplatelet agent Effient: Effient can be used with the proton pump inhibitor Prilosec; Plavix cannot